Evidence map›Paper›PMID 25126491›Full record

ArticleInternational journal of mycobacteriology2012

Personalized medicine approach in mycobacterial disease.

Mehdi Mirsaeidi

Open access · diamondAbstract read
In one paragraph

Article in International journal of mycobacteriology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Exome Sequencing Identifies a NovelFrontiers in immunology · 2017
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mehdi MirsaeidiDivision of Pulmonary and Critical Care, University of Illinois at Chicago, Chicago, IL, USA.
University of Illinois Chicago · US

Funding

Pulmonary and Critical Care Post-Doctoral Research Training ProgramT32HL082547 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI FINN, PATRICIA W · 2007 to 2017
$2.7M
NHLBI NIH HHS T32 HL082547
6 · The paper itself

Abstract

Mycobacterial diseases are a group of illnesses that cause a considerable number of deaths throughout the world, regardless of years of public health control efforts. Personalized medicine is a new but rapidly advancing field of healthcare. Personalized medicine in the field of mycobacteriology may be applied in the different levels of management such as prevention, diagnosis, treatment and prognosis. A genetic predisposition and a protein dysfunction study are recommended to tailor an individual approach in mycobacterial diseases.

Indexed as

MycobacterialNTMPersonalized medicineTB

Identifiers

PMID25126491
PMCPMC4130370
OpenAlexW2136400369

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.